422 related articles for article (PubMed ID: 19129693)
1. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
[TBL] [Abstract][Full Text] [Related]
2. Podocytes of AT2 receptor knockout mice are protected from angiotensin II-mediated RAGE induction.
Rüster C; Franke S; Wenzel U; Schmidthaupt R; Fraune C; Krebs C; Wolf G
Am J Nephrol; 2011; 34(4):309-17. PubMed ID: 21846974
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites.
Bondeva T; Roger T; Wolf G
Am J Nephrol; 2007; 27(3):308-14. PubMed ID: 17495427
[TBL] [Abstract][Full Text] [Related]
4. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes.
Gu L; Hagiwara S; Fan Q; Tanimoto M; Kobata M; Yamashita M; Nishitani T; Gohda T; Ni Z; Qian J; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2006 Feb; 21(2):299-313. PubMed ID: 16263740
[TBL] [Abstract][Full Text] [Related]
5. Characterization of angiotensin II-receptor subtypes in podocytes.
Wang L; Flannery PJ; Spurney RF
J Lab Clin Med; 2003 Nov; 142(5):313-21. PubMed ID: 14647035
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
Rüster C; Bondeva T; Franke S; Förster M; Wolf G
Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity.
Bondeva T; Wolf G
Am J Nephrol; 2009; 30(4):336-45. PubMed ID: 19590177
[TBL] [Abstract][Full Text] [Related]
10. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy.
Chan LY; Leung JC; Tang SC; Choy CB; Lai KN
J Am Soc Nephrol; 2005 Aug; 16(8):2306-17. PubMed ID: 15930094
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes.
Tsuchiya K; Yoshimoto T; Hirono Y; Tateno T; Sugiyama T; Hirata Y
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E771-8. PubMed ID: 16705055
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
Sendra J; Llorente-Cortés V; Costales P; Huesca-Gómez C; Badimon L
Cardiovasc Res; 2008 Jun; 78(3):581-9. PubMed ID: 18281370
[TBL] [Abstract][Full Text] [Related]
13. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
14. TRPC6 up-regulation in Ang II-induced podocyte apoptosis might result from ERK activation and NF-kappaB translocation.
Zhang H; Ding J; Fan Q; Liu S
Exp Biol Med (Maywood); 2009 Sep; 234(9):1029-36. PubMed ID: 19546355
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cGMP synthesis in cultured podocytes by vasoactive hormones.
Lewko B; Gołos M; Latawiec E; Angielski S; Stepinski J
J Physiol Pharmacol; 2006 Dec; 57(4):599-610. PubMed ID: 17229984
[TBL] [Abstract][Full Text] [Related]
16. Activation of a local renin angiotensin system in podocytes by glucose.
Durvasula RV; Shankland SJ
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F830-9. PubMed ID: 18216149
[TBL] [Abstract][Full Text] [Related]
17. Expression and regulation of AT1 receptor in rat lung microvascular endothelial cell.
Zhang H; Sun GY
J Surg Res; 2006 Aug; 134(2):190-7. PubMed ID: 16580689
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells.
Esteban V; Ruperez M; Sánchez-López E; Rodríguez-Vita J; Lorenzo O; Demaegdt H; Vanderheyden P; Egido J; Ruiz-Ortega M
Circ Res; 2005 May; 96(9):965-73. PubMed ID: 15831814
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of GSPE on RAGE expression induced by advanced glycation end products in endothelial cells.
Zhang FL; Gao HQ; Shen L
J Cardiovasc Pharmacol; 2007 Oct; 50(4):434-40. PubMed ID: 18049312
[TBL] [Abstract][Full Text] [Related]
20. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells.
Tsuji H; Iehara N; Masegi T; Imura M; Ohkawa J; Arai H; Ishii K; Kita T; Doi T
Biochem Biophys Res Commun; 1998 Apr; 245(2):583-8. PubMed ID: 9571198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
